Mission Cancer + Blood is a community-based medical practice specializing in oncology and hematology care. Founded in 1981 and headquartered in Des Moines, Iowa, it provides cancer and blood disorder treatment services across multiple locations in the state. In January 2025, the practice became part of University of Iowa Health Care, supporting the development of a statewide comprehensive cancer care network.
Also known as Mission Cancer and Blood and Mission Cancer Blood PLLC.
sBLA accepted based on phase III SUNMO showing 59% reduction in progression risk; FDA decision expected by 9 Feb 2027.
sBLA accepted for subcutaneous bispecific + ADC combo in relapsed/refractory large B‑cell lymphoma; FDA decision expected Feb 9, 2027.
